Related Experiment Video
Updated: Jun 15, 2026
08:18
Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
Glibenclamide-loaded self-nanoemulsifying drug delivery system: development and characterization
Sandeep Kumar Singh1, Priya Ranjan Prasad Verma, Balkishen Razdan
1Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India.
Drug Development and Industrial Pharmacy
|February 27, 2010
Summary
This study developed a self-nanoemulsifying drug delivery system (SNEDDS) for glibenclamide (GBD). The optimized SNEDDS formulation demonstrated potential for enhanced drug absorption due to its nanosize and ingredient compatibility.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Nanotechnology
Background:
- Glibenclamide (GBD) is a poorly water-soluble drug.
- Enhancing GBD's solubility and bioavailability is crucial for effective treatment.
- Self-nanoemulsifying drug delivery systems (SNEDDS) offer a promising approach.
Purpose of the Study:
- To develop and characterize a SNEDDS for glibenclamide (GBD).
- To evaluate the physical and chemical stability of the SNEDDS.
- To assess the potential of SNEDDS to improve GBD absorption.
Main Methods:
- Solubility studies and phase diagram construction to identify optimal SNEDDS components (oils, surfactants, cosurfactants).
- Formulation characterization including drug content, particle size analysis, zeta potential, and dissolution studies.
- Advanced characterization using Transmission Electron Microscopy (TEM), FTIR, DSC, and XRD to confirm globule morphology and ingredient compatibility.
Main Results:
- Optimized SNEDDS formulations exhibited mean particle sizes between 15.65 and 32.70 nm post-dilution.
- TEM confirmed spherical, non-coalesced nanoemulsion globules with no drug precipitation.
- Spectroscopic and thermal analyses indicated no drug-excipient incompatibility.
Conclusions:
- The developed SNEDDS for glibenclamide is stable and characterized by nanosized particles.
- The SNEDDS formulation has significant potential to enhance glibenclamide absorption.
- The absence of drug-excipient interactions ensures formulation integrity and safety.
Related Concept Videos
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...